Search

Your search keyword '"Gregersen, Henrik"' showing total 339 results

Search Constraints

Start Over You searched for: Author "Gregersen, Henrik" Remove constraint Author: "Gregersen, Henrik"
339 results on '"Gregersen, Henrik"'

Search Results

51. A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group

52. Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

54. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.

56. Carfilzomib and dexamethasone maintenance prolong time to progression following salvage ASCT in multiple myeloma: A randomized phase 2 trial by the nordic myeloma study group

61. Clarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patients

64. Health-related quality of life in multiple myeloma patients with first relapse treated with Carfilzomib-based re-induction and salvage autologous stem cell transplantation:data from a Nordic phase II trial

65. Carfilzomib-Cyclophosphamide-Dexamethasone induction and salvage ASCT transplant-eligible multiple myeloma with firs trelapse after upfront ASCT

67. Methylphenidate for fatigue in haematological cancer. A randomized, doubleblind, placebo-controlled, crossover trial - the MICRO trial

68. Strategies to improve patient-reported outcome completion rates in longitudinal studies

70. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma

72. Health-related quality of life in multiple myeloma patients with first relapse treated with Carfilzomib-based re-induction and salvage autologous stem cell transplantation : data from a Nordic phase II trial

73. Dansk Myelomatose Database:Årsrapport 2016

74. Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population

75. Clarithromycin added to bortezomib‐cyclophosphamide‐dexamethasone impairs health‐related quality of life in multiple myeloma patients

77. The impact of comorbidity on mortality in multiple myeloma:a Danish nationwide population-based study

78. The Danish National Multiple Myeloma Registry

81. The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study

83. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support:A study based on the nationwide Danish Myeloma Database

85. Smoldering multiple myeloma risk factors for progression:a Danish population-based cohort study

86. The Danish National Multiple Myeloma Registry

87. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support:A study based on the nationwide Danish Myeloma Database

88. Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival

89. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma:a Nordic Myeloma Study Group randomized phase 3 trial

94. [In Process Citation]

95. Goods syndrom med både lymfopeni og neutropeni

96. The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in and

97. Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004*

100. Genetic variants in the P2RX7 gene are associated with risk of multiple myeloma

Catalog

Books, media, physical & digital resources